Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of two live attenuated vaccines administered together for the prevention of varicella (chickenpox) and Japanese encephalitis (JE). The live attenuated varicella vaccine contains an Oka strain of varicella-zoster virus, which induces immunity by mimicking natural infection and stimulating both humoral and cellular immune responses[1][5]. The live attenuated JE vaccine (such as JE-CV or SA14-14-2) uses a weakened form of the Japanese encephalitis virus to elicit protective neutralizing antibodies against JE[6][8]. Both vaccines are primarily indicated for children in endemic regions or travelers at risk. Co-administration has been shown to be safe and immunogenic, with no significant reduction in efficacy or increase in adverse events compared to separate administration[6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on live attenuated varicella vaccine + live attenuated Japanese encephalitis vaccine.